{"id":259,"date":"2016-07-25T19:33:22","date_gmt":"2016-07-26T01:33:22","guid":{"rendered":"http:\/\/davidzamorano.com\/espondilitis\/?p=259"},"modified":"2016-07-25T19:53:02","modified_gmt":"2016-07-26T01:53:02","slug":"gut-mediated-and-hla-b27-associated-arthritis-an-emphasis-on-ankylosing-spondylitis-and-crohns-disease-with-a-proposal-for-the-use-of-new-treatment","status":"publish","type":"post","link":"https:\/\/davidzamorano.com\/espondilitis\/gut-mediated-and-hla-b27-associated-arthritis-an-emphasis-on-ankylosing-spondylitis-and-crohns-disease-with-a-proposal-for-the-use-of-new-treatment\/","title":{"rendered":"Gut-mediated and HLA-B27-associated Arthritis: An Emphasis on Ankylosing Spondylitis and Crohn\u2019s Disease with a Proposal for the Use of New Treatment"},"content":{"rendered":"

Author:\u00a0Taha Rashid<\/a><\/strong>
\n<\/strong><\/span><\/h2>\n

Specialty:\u00a0Immunology<\/a>,\u00a0Internal Medicine<\/a>
\nInstitution: Analytical Sciences Group, Kings College London
\nAddress: London, SE1 9NN, United Kingdom<\/p>\n

Author:\u00a0Alan Ebringer<\/a><\/strong><\/strong><\/span><\/h2>\n

Specialty:\u00a0Immunology<\/a>,\u00a0Internal Medicine<\/a>
\nInstitution: Analytical Sciences Group, Kings College London
\nAddress: London, SE1 9NN, United Kingdom<\/p>\n

<\/h2>\n

<\/h2>\n

Abstract:\u00a0<\/strong>Ankylosing spondylitis (AS) and Crohn’s disease (CD), especially when associated with spondylitis are interrelated conditions included within the categories of spondyloarthropathic disease entities. They share some common clinical, genetic, and microbiological findings. An extensive amount of studies which have been carried out by various independent groups throughout the world have shown that\u00a0Klebsiella pneumoniae<\/em>microorganisms could be suggested as the most likely etiopathogenetic triggers for AS and CD based on the molecular mimicry mechanism and the existence of the evidence for immunological, microbiological, and molecular link between\u00a0Klebsiella<\/em>\u00a0and self antigens. It is proposed that the use of low starch diet in conjunction with the currently used treatment might help in the eradication of\u00a0Klebsiella<\/em>\u00a0microbes from the bowel and could result in the stoppage and alleviation of the disease process in patients with AS and\/or CD.<\/p>\n

 <\/p>\n

Introduction<\/strong><\/p>\n

Ankylosing spondylitis<\/a>\u00a0(AS) and Crohn\u2019s disease (CD) are among a group of related conditions which share some overlapping features, such as asymmetric oligoarthritis, inflammatory back pain, or spondylitis\/sacroiliitis<\/a>, enthesitis (inflammation of the entheses \u2014 the sites where the tendons or ligaments insert into the bone), anterior\u00a0uveitis<\/a>, a positive family history, and association with\u00a0HLA-B27<\/a>genetic markers, but without a positive rheumatoid factor.<\/p>\n

These diseases are all embraced under the name of spondyloarthropathies (SpAs) (Braun and Sieper, 2010), and mainly include ankylosing spondylitis (AS),\u00a0psoriatic arthritis<\/a>\u00a0(PsA), reactive arthritis (ReA), undifferentiated SpA (U-SpA), and enteropathic arthropathy or\u00a0inflammatory bowel disease<\/a>\u00a0(IBD) which comprises Crohn\u2019s disease (CD) and\u00a0ulcerative colitis<\/a>\u00a0(UC). Apart from PsA, there is extensive evidence for the association of gut inflammation in all disease entities of SpAs to a greater or lesser extent (Mielants et al., 2005).<\/p>\n

 <\/p>\n

The Link Between HLA-B27 and Gut-mediated Arthritic Diseases<\/strong><\/p>\n

The association of HLA-B27 with AS is amongst the strongest genetic link with any common disease which has been encountered in the field of\u00a0rheumatology\u00a0(Thomas and Brown, 2010). This genetic bond was discovered in early 1970s, where more than 95% of patients with AS have been found to possess HLA-B27 alleles, whilst the frequency of this gene in the general population was below 10% (Brewerton et al., 1973; Schlosstein et al., 1973). Other diseases in the SpA group have lower but different degrees of associations with this allelotype (Figure 1), depending on the clinical presentation and pathological location of the disease (Braun and Sieper, 2010). For example, the frequency of this allelotype in patients with IBD\/CD without associated arthritis is comparable to those of the normal population but increases to 40-60% in those patients with spondylitis\/sacroiliitis. The frequency of HLA-B27 in patients with ReA\/Reiter\u2019s syndrome and U-SpA is ranging between 30 to 90% and 50 to 70%, respectively, meanwhile its frequency in patients with PsA with or without peripheral arthritis is around 20%, but it is increased to up to 60% in patients with associated sacroiliitis.<\/p>\n

From these data results, it appears that a spondyloarthropathic patient presenting with spinal involvement had a higher chance of possessing HLA-B27 genes than those with peripheral joints involvement only. Whether patients with spinal involvements are more likely to encounter exposure to enteropathogenic bacteria and develop the disease needs further clarification.<\/p>\n

 <\/p>\n

\"discovery_medicine_no_64_alan_ebringer_figure_1\"<\/p>\n

 <\/p>\n

Evidence for Associated Gut Inflammation and Interrelations Between Different Disease Entities of SpAs<\/strong><\/p>\n

Many data support the existence of an inter-connection or inter-relation between different disease entities in the SpAs group. For example:<\/p>\n

1). The prevalence of AS in patients with UC and CD was found to be reaching 2.6% and 6%, respectively, giving an overall 3.7% prevalence in patients with IBD (Palm et al., 2002). It has also been reported that AS is frequently associated with IBD, with 5-10% of cases having clinical IBD and approximately 70% of cases having subclinical bowel inflammation (Thomas and Brown, 2010), and this link was emphasized previously through an analytical review (Ebringer et al., 2007). Furthermore, HLA-B27 positive patients with IBD were shown to have higher chances of developing AS when compared to those without IBD (Wright, 1978).<\/p>\n

2). Many studies have shown macroscopical and\/or microscopical features of gut mucosal inflammation, especially in patients with IBD, ReA, AS, and U-SpA (Porzio et al., 1997; Mielants et al., 2005). In one particular study, gut changes varying from an acute to asymptomatic chronic intestinal inflammation have been observed in about 60% of patients with SpA (Demetter et al., 2002), and more interestingly, those patients who showed signs of articular remissions were preceded by disappearance of the gut inflammation, which supports the concept that the gut is involved in the pathogenesis of SpAs.<\/p>\n

3). Another fundamental support for the role of gut and the intestinal flora in the development of SpAs in relation to the presence of HLA-B27 genes is the absence of arthritis and colitis in germ-free HLA-B27-transgenic rats and the induction of these features when the rats were relocated to non germ-free environment (Hammer et al., 1990).<\/p>\n

4). Twenty to 30 percent of patients with unclassified HLA-B27-positive inflammatory rheumatic diseases (Sany et al., 1980) or oligoarthritis (Schattenkirchner and Kruger, 1987) have been shown to develop into one form of the definite spondyloarthropathic group such as IBD, ReA, or AS (Figure 1).<\/p>\n

5). It has also been stated that more than half of patients with U-SpA will develop AS over a certain period of time (Mau et al., 1988). In a later study, however, no significant differences were observed in some clinico-radiological or genetic features of AS and U-SpA among the Middle Eastern and South Asian populations (Uppal et al., 2006).<\/p>\n

It appears from these results that both HLA-B27 and gut inflammation play a pivotal role in the development of SpAs, especially AS and CD, and that the main etiopathogenetic process is triggered by a combined genetic and environmental (mainly microbial) factors.<\/p>\n

 <\/p>\n

Evidence for the Microbial Link with AS and CD<\/strong><\/p>\n

The first evidence of the epidemiological link between microbes and SpAs was detected in the early Twentieth Century, where a triad of urethritis, conjunctivitis, and arthritis, being termed as Reiter\u2019s syndrome, was found to follow a dysenteric or venereal infection (Calin, 1998). Reiter\u2019s syndrome was later recognized as a form of ReA and since then each of the triggering bacterial agents including\u00a0Yersinia, Campylobacter, Shigella, and\u00a0Salmonella\u00a0enterogenic bacteria as well as\u00a0Chlamydiaurogenital pathogens has been found to have an approximately equal role in the development of this disease (Leirisalo-Repo, 2005; Townes, 2010).<\/p>\n

Although epidemiological evidence for the involvement of microbial agents in other disease entities of SpAs are lacking, a considerable degree of molecular, immunological, as well as microbiological data are available to support the role of\u00a0Klebsiella\u00a0pneumoniae\u00a0in the etiopathogenesis of both AS (Ebringer et al., 2011) and CD (Rashid et al., 2009). Apart from some evidence for the role of mycobacteria (Rambukkana et al., 1993), however, no other microbes have been implicated in the causation of\u00a0psoriasis.<\/p>\n

 <\/p>\n

Klebsiella\u00a0and Self Cross-reactive Antigens<\/strong><\/p>\n

Klebsiella\u00a0microbes possess various antigens which show molecular similarity and immunological cross-reactivity with HLA-B27 or other self-antigens and these have been demonstrated in several independent studies:<\/p>\n

Evidence for\u00a0molecular mimicry\u00a0(Figure 2<\/strong>)<\/p>\n

 <\/p>\n

\"discovery_medicine_no_64_alan_ebringer_figure_2\"<\/p>\n

 <\/p>\n

1) A molecular homology has been found between a hexameric amino acid sequence, \u201cQTDRED\u201d present in both\u00a0HLA-B*2705 molecules (residues 72-77) and\u00a0Klebsiella pneumoniae\u00a0nitrogenase reductase enzymes (residues 188-193) (Schwimmbeck et al., 1989).<\/p>\n

2) A structural similarity has been found between the \u201cDRDE\u201d amino acid sequences (residues 596-599) present in the Pul-D secretion protein from\u00a0Klebsiella\u00a0pullulanase enzyme, and the \u201cDRED\u201d amino acid motif (residues 74-77) present in the HLA-B27 molecules (Fielder et al., 1995).<\/p>\n

3) Another molecular similarity composed of repeated triplet amino acid sequences \u201cG-x-P\u201d has been discovered between Pul-A secretion protein from\u00a0Klebsiellapullulanase enzyme and collagen types I, III, and IV (Fielder et al., 1995) mainly contained in the ligaments and cartilaginous structures of spinal vertebral large joints and uvea.<\/p>\n

 <\/p>\n

Evidence for immunological cross-reactivity:<\/strong><\/p>\n

1) Antibodies obtained from a rabbit immunized with HLA-B27-positive lymphocytes showed positive reactions with the antigenic extracts of five gut-inhabited bacterial agents including\u00a0Klebsiella, Enterobacter, Salmonella, Shigella, and\u00a0Yersinia\u00a0microbes indicating the presence of shared cross-reactive antigens (Welsh et al., 1980).<\/p>\n

2) Allogeneic anti-HLA-B27 antibodies obtained from human tissue typing sera were found to bind to\u00a0Klebsiella\u00a0antigens more than other tissue typing sera (Avakian et al., 1980).<\/p>\n

3) Anti-HLA-B27 monoclonal antibodies were found to bind more specifically to 60 and 80 Kd components of\u00a0Klebsiella, whereas no such reactivity was demonstrated by five other monoclonal antibodies (Ogasawara et al., 1986).<\/p>\n

4) No significant difference was observed in the immunological reaction between HLA-B27 positive lymphocytes whether obtained from AS patients or healthy controls when treated against sera from rabbits immunized with\u00a0Klebsiella\u00a0microbes in comparison to lymphocytes from HLA-B27 negative individuals, which indicates that there are no differences between antigenic specificities of HLA-B27 molecules whether taken from diseased or healthy individuals (Baines et al., 1990).<\/p>\n

5) IgA antibody levels against synthetic peptides carrying\u00a0Klebsiella\u00a0or HLA-B27 cross-reactive antigens were found to be elevated in sera of Japanese AS patients compared to\u00a0rheumatoid arthritispatients or healthy controls (Tani et al., 1997a), most probably due to the existing bacterial and self cross-reactive antigens in AS patients.<\/p>\n

6) Secretory IgA2 antibodies were found to be significantly increased against type I, III, and IV collagens in sera of Japanese patients with AS when compared to healthy individuals (Tani et al., 1997b).<\/p>\n

7) Antibodies from sera of AS patients were found to be cytotoxic to HLA-B27-peptide-bearing cells as shown by increased percentage lysis for sheep red blood cells coated with HLA-B*2705 peptide when compared to patients with rheumatoid arthritis and healthy controls (Wilson et al., 2003), indicating that these autoantibodies probably contribute to the immunological damages which take place at the pathological sites in patients with AS or CD.<\/p>\n

 <\/p>\n

Klebsiella\u00a0Antibodies in AS and CD<\/strong><\/p>\n

During the last three decades extensive studies have been carried out by independent scientific groups using various immunological methods in order to determine the levels of antibodies against\u00a0Klebsiella\u00a0and other related enterobacterial microbes in AS patients from 16 different countries. Nearly all these studies showed that antibody levels against\u00a0Klebsiella\u00a0antigens (or cross-reactive self-antigens) but not against other microbes have been found to be elevated more significantly in patients with AS when compared to patients with other diseases or to healthy controls (Ebringer et al., 2006; Rashid et al., 2007).<\/p>\n

Furthermore, several groups have shown that significantly elevated antibodies to\u00a0Klebsiellamicroorganisms have been detected in patients with IBD, especially CD, when compared to corresponding healthy controls (Ibbotson et al., 1987; Cooper et al., 1988; O\u2019Mahony et al., 1992; Tiwana et al., 1997; 1998). In a later study, a positive correlation was detected between levels of antibodies against\u00a0Klebsiella\u00a0and collagen cross-reactive antigens in patients with CD (Tiwana et al., 2001).<\/p>\n

The consistent observation of significantly elevated levels of antibodies against\u00a0Klebsiella\u00a0but not other related enterobacterial agents in patients with AS and CD but not in patients with other rheumatic diseases supports the suggestion that this microbe-disease link is not an epiphenomenon but a specific pathological characteristic.<\/p>\n

 <\/p>\n

Molecular Mimicry Hypothesis and Pathogenetic Mechanism in AS and CD<\/strong><\/p>\n

Rheumatic fever has been recognized for the last five decades as a systemic arthritic disease caused by early\u00a0Streptococcal<\/em>\u00a0upper respiratory infection with resultant pathological lesions affecting collagens in the joints (Jaggi, 2011), heart muscles (Towers et al., 2009), and brain tissues causing Sydenham\u2019s chorea (Cardoso, 2011). These lesions are caused by the binding of anti-Streptococcal<\/em>\u00a0antibodies to the self cross-reactive antigens at these sites. The same pathogenetic mechanism can be involved in the development of AS and CD where anti-Klebsiella<\/em>\u00a0antibodies are binding to the cross-reactive self antigens at the entheses of the large joints, especially spinal vertebrae as the result of complement dependent cytopathic\u00a0autoantibody<\/a>\u00a0reactions with self antigens (Figure 3<\/strong>). It would appear that rheumatic fever, AS, and CD are all autoimmune diseases evoked by antibodies to environmental bacteria, the infectious agents being located at different pathological sites. Such chronic autoimmune diseases, however, cannot satisfy Koch\u2019s criteria of an infectious disease.<\/p>\n

 <\/p>\n

\"discovery_medicine_no_64_alan_ebringer_figure_3\"<\/p>\n

 <\/p>\n

In patients with AS and CD we suggest that\u00a0Klebsiella<\/em>\u00a0infection in the bowel, whether overt or subclinical, primarily causes production of anti-Klebsiella<\/em>\u00a0antibodies which can also bind to the cross-reactive self antigens like HLA-B27 and collagen fibers in the joints with release of further new antigens on the surface of damaged tissue. These new antigens are responsible for prolonged or continuous production of autoantibodies and further damages to the articular tissues with a perpetuation in the disease process. Recurrent infections with these bacteria could explain the characteristic remission\/exacerbation features which have been observed frequently in patients with these diseases.<\/p>\n

The entheses in and around the sacroiliac and spinal joints are the principal sites of inflammation in patients with AS (Hamdi et al., 2011) and CD (Bandinelli et al., 2011). The tendency for the occurrence of pathological lesions at these locations within the territory of the spinal joints is most probably due to their proximity with the draining local lymphatic plexus (Batson\u2019s plexus) from the large bowel in which\u00a0Klebsiella<\/em>\u00a0and other enterobacterial species are abundant.<\/p>\n

 <\/p>\n

Proposal for the Use of a New Therapeutic Protocol in AS and CD<\/strong><\/p>\n

The current medical treatment in patients with AS includes the use of non-steroidal anti-inflammatory drugs, immunomosuppresive drugs, and biological agents (Sieper, 2008; Song and Poddubnyy, 2011), whilst in patients with CD in addition to these drugs aminosalicylates,\u00a0antibiotics<\/a>, and\u00a0corticosteroids<\/a>\u00a0can also be included in the management (Triantafillidis et al., 2011). Nearly all of these therapeutic modalities, however, are not curative but significantly reduce the degree of inflammation and prolong the duration of remission. Furthermore, most if not all of these treatments have some mild to moderate (Rimbas et al., 2011) or even lethal (Renaud et al., 2011) adverse effects. Nevertheless, it is generally agreed that AS and especially CD are both non-curable diseases and associated with considerably high recurrence rates even with the use of the proper treatments. For example, the recurrence rates in patients with CD have been shown to range between 50% (Colombel et al., 2010) to over 70% (Burt et al., 2010). In a more recent meta-analytical study, it was shown that stopping the treatment with the immunosuppressant,\u00a0azathioprine<\/a>, could increase the likelihood of recurrence rate among patients with CD (French et al., 2011).<\/p>\n

We suggest that in addition to the currently used medicines other therapeutic modalities could be included in the management of these diseases. One of the main candidates for this new therapeutic protocol is the use of a low starch diet.\u00a0Klebsiella<\/em>\u00a0microbes are considered as one group of bacterial agents that is basically used for the production of ethanol by fermentation. Monosaccharides and disaccharides, which are principally derived from digestion of complex carbohydrates, such as starch, are the main substrate materials available in the gut for microbial growth and survivals. Normal individuals fail to absorb up to 20% of dietary starch materials, which are present in wheat flour products such as bread and pasta, as assessed by oral hydrogen excretion studies, following a test meal (Anderson et al., 1981).<\/p>\n

In a study carried out by a group from Los Angeles, it was observed that the mean number of fecal\u00a0Klebsiella<\/em>\u00a0microorganisms in individuals taking high carbohydrate\/low protein diet was 40 times higher than in those subjects receiving low carbohydrate\/high protein diet (Finegold et al., 1977). In a similar study, the mean number of\u00a0Klebsiella<\/em>\u00a0was found to be 10 times higher for simple sugars (sucrose, lactose, and glucose) per gram of substrate compared to the value obtained after incubation with 11 different amino acids (Ebringer et al., 1985), which indicates that carbohydrates are highly necessary for the growth and replications of\u00a0Klebsiella<\/em>\u00a0or even other related enteropathic microorganisms. In the same study, a significant drop in the erythrocyte sedimentation rate and serum total IgA have been observed by the end of a 9-month period in patients with AS receiving low starch diet. Most patients in the study have reported positive responses from partial to complete recovery from the disease, ranging from disappearance of symptoms to the drop of or even completely stopping the usage of anti-inflammatory drugs. However, the same group of patients did not show any difference in these laboratory parameters when examined retrospectively during the same period of time before they went on the low starch diet.<\/p>\n

In the AS patients attending the \u201cLondon AS Clinic\u201d at the Middlesex Hospital for the past 20 years, it has been found that normally it takes around 6-8 months for the diet to show its effects, and that the majority of AS patients could be treated with dietary manipulation and exercises without the requirements for supplementary pharmaceutical treatments (Ebringer and Wilson, 1996). It is plausible that low starch diet might affect bowel flora by depleting the substrates necessary for enterobacterial growth. For example it could stop or decrease the induction of substrate-dependent microbial products, such as pullulanase, which is a starch debranching enzyme produced by\u00a0Klebsiella<\/em>microorganisms, with a possibility of having ameliorating effects on the disease outcome.<\/p>\n

Based on these data results it is suggested that a low starch diet intake could help in the eradication of\u00a0Klebsiella<\/em>\u00a0and other related enterobacterial species from the bowel and might lead to a decrease in the activity, progress, and full development of AS, CD, and possibly other disease entities of SpAs.<\/p>\n

Conclusion<\/strong><\/p>\n

It appears from the results of various independent studies that the pathogenesis of AS and CD involves a genetically-determined, abnormal host immune response to a bacterial stimulus, which is most likely to be\u00a0Klebsiella<\/em>. An extensive evidence exists which supports the role for\u00a0Klebsiella<\/em>microbes in the etiopathogenesis of AS and CD based on the results of various independent microbiological, molecular, and immunological studies.<\/p>\n

We suggest that, together with the currently used treatments, inclusion of a low starch dietary intake in patients with AS and\/or CD could be beneficial especially when started in the early disease stages and especially in the highly susceptible individuals with positive family history of SpAs or those possessing HLA-B27 genetic allelotypes.<\/p>\n

 <\/p>\n

Acknowledgments<\/strong><\/p>\n

This study was supported by the Trustees of the Middlesex Hospital, and the \u201cAmerican Friends of Kings College London.\u201d<\/p>\n

 <\/p>\n

Disclosure<\/strong><\/p>\n

The authors declare no conflict of interests.<\/p>\n

 <\/p>\n

Corresponding Author<\/strong><\/p>\n

Professor Alan Ebringer, M.D., Analytical Sciences Group, Kings College London, 150 Stamford Street, London SE1 9NN, United Kingdom.<\/p>\n

 <\/p>\n

References<\/strong><\/p>\n

Anderson IH, Levine AS, Levitt MD. Incomplete absorption of the carbohydrate in all-purpose wheat flour.\u00a0N Engl J Med<\/em>\u00a0304(15):891-892, 1981.<\/p>\n

Avakian H, Welsh J, Ebringer A, Entwistle CC. Ankylosing spondylitis, HLA-B27 and\u00a0Klebsiella<\/em>. II. Cross-reactivity studies with human tissue typing sera.\u00a0Br J Exp Pathol\u00a0<\/em>61(1):92-96, 1980.<\/p>\n

 <\/p>\n

Baines M, Ebringer A, Avakian H, Samuel D, James DC. The use of enzyme immunoassay (EIA) and radiobinding assay to investigate the cross-reactivity of\u00a0Klebsiella<\/em>\u00a0antigens and HLA-B27 in ankylosing spondylitis patients and healthy controls.\u00a0Scand J Rheumatol<\/em>\u00a019(5):341-349, 1990.<\/p>\n

 <\/p>\n

Bandinelli F, Milla M, Genise S, Giovannini L, Bagnoli S, Candelieri A, Collaku L, Biagini S, Cerinic MM. Ultrasound discloses entheseal involvement in inactive and low active inflammatory bowel disease without clinical signs and symptoms of\u00a0spondyloarthropathy<\/a>.\u00a0Rheumatology (Oxford)\u00a0<\/em>50(7):1275-1279, 2011.<\/p>\n

 <\/p>\n

Braun J, Sieper J. Ankylosing spondylitis, other spondyloarthritides, and related conditions.\u00a0In<\/em>:\u00a0Oxford Textbook of Medicine<\/em>. Warrell DA, Cox TM, et al. (eds.). pp. 3603-3616. Oxford University Press, Oxford, United Kingdom, 2010.<\/p>\n

Brewerton DA, Hart FD, Nicholls A, Cafferty MF, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27.\u00a0Lancet<\/em>\u00a01(7809):904-907, 1973.<\/p>\n

 <\/p>\n

Burt RK, Craig RM, Milanetti F, Quigley K, Gozdziak P, Bucha J, Testori A, Halverson A, Verda L, de Villiers WJ, Jovanovic B, Ovama Y. Autologous nonmyeloablative\u00a0hematopoietic stem cell transplantation<\/a>\u00a0in patients with severe anti-TNF<\/a>\u00a0refractory Crohn Disease: long-term follow-up.\u00a0Blood<\/em>116(26):6123-6132, 2010.<\/p>\n

Calin A. Reiter\u2019s syndrome-the clinical spectrum.\u00a0In<\/em>:\u00a0The<\/em>\u00a0Spondyloarthritides<\/em>. Calin A and Taurog JD (eds.). pp. 41-57. Oxford University Press, Oxford, United Kingdom, 1998.<\/p>\n

Cardoso F. Sydenham\u2019s chorea.\u00a0Handb Clin Neurol<\/em>\u00a0100:221-229, 2011.<\/p>\n

 <\/p>\n

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D\u2019Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CI, Rutgeerts P.\u00a0Infliximab<\/a>, azathioprine, or\u00a0combination therapy<\/a>\u00a0for Crohn\u2019s disease.\u00a0N Engl J Med<\/em>\u00a0362(15):1383-1395, 2010.<\/p>\n

 <\/p>\n

Cooper R, Fraser SM, Sturrock RD, Gemmell CG. Raised titres of anti-Klebsiella<\/em>\u00a0IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.\u00a0Br Med J<\/em>\u00a0296(6634):1432-1434, 1988.<\/p>\n

Demetter P, Van Huysse J, De Keyser F, Van Damme N, Verbruggen G, Mielants H, De Vos M, Veys EM, Cuvelier CA. Increase in lymphoid follicle and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis.\u00a0J Pathol<\/em>\u00a0198(4):517-522, 2002.<\/p>\n

Ebringer A, Baines M, Childerstone M, Ghuloom M, Ptaszynska T. Etiopathogenesis of ankylosing spondylitis and the cross-tolerance hypothesis.\u00a0In<\/em>:\u00a0Advances in inflammation research-The spondyloarthropathies<\/em>.\u00a0<\/em>Ziff M and Cohen SB (eds.). pp. 101-128. Raven Press, New York, New York, USA, 1985.<\/p>\n

Ebringer A, Wilson C. The use of low starch diet in the treatment of patients suffering from ankylosing spondylitis.\u00a0Clin Rheumatol<\/em>\u00a015(Suppl 1):62-66, 1996.<\/p>\n

Ebringer A, Rashid T, Wilson C, Ptaszynska T, Fielder M. Ankylosing spondylitis, HLA-B27 and\u00a0Klebsiella<\/em>\u00a0– an overview: proposal for\u00a0early diagnosis<\/a>\u00a0and treatment.\u00a0Curr Rheumatol Rev<\/em>\u00a02(1):55-68, 2006.<\/p>\n

 <\/p>\n

Ebringer A, Rashid T, Tiwana H, Wilson C. A possible link between Crohn\u2019s disease and ankylosing spondylitis via\u00a0Klebsiella<\/em>\u00a0infections.\u00a0Clin Rheumatol<\/em>\u00a026(3):289-297, 2007.<\/p>\n

 <\/p>\n

Ebringer A, Rashid T, Fielder M, Wilson C. Ankylosing spondylitis, HLA-B27,\u00a0Klebsiella<\/em>\u00a0and \u201cPopper sequences\u201d.\u00a0Curr Rheumatol Rev,\u00a0<\/em>epub ahead of print, 2011.<\/p>\n

 <\/p>\n

Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, Binder A, Bansal S, Ebringer A. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of\u00a0Klebsiella pneumoniae.<\/em>\u00a0FEBS Lett<\/em>\u00a0369(2-3):243-248, 1995.<\/p>\n

 <\/p>\n

Finegold SM, Sutter VL, Sugihara PT, Elder HA, Lehmann SM, Philips RL. Fecal microbial flora in Seventh Day Adventist populations and control subjects.\u00a0Am J Clin Nutr<\/em>\u00a030(11):1781-1792, 1977.<\/p>\n

French H, Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn\u2019s disease: A meta-analysis.\u00a0Dig Dis Sci<\/em>\u00a056(7):1929-1936, 2011.<\/p>\n

 <\/p>\n

Hamdi W, Chelli-Bouaziz M, Ahmed MS, Ghannouchi MM, Kaffel D, Ladeb MF, Kchir MM. Correlations among clinical, radiographic, and sonographic scores for enthesitis in ankylosing spondylitis.\u00a0Joint Bone Spine<\/em>\u00a078(3):270-274, 2011.<\/p>\n

 <\/p>\n

Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: An animal model of HLA-B27-associated human disorders.\u00a0Cell<\/em>\u00a063(5):1099-1112, 1990.<\/p>\n

Ibbotson JP, Pease PE, Allan RN. Serological studies in Crohn\u2019s disease.\u00a0Eur J Clin Microbiol<\/em>6(3):286-290, 1987.<\/p>\n

Jaggi P. Rheumatic fever and post group-a streptococcal arthritis.\u00a0Pediatr Infect Dis J<\/em>\u00a030(5):424-425, 2011.<\/p>\n

Leirisalo-Repo M. Reactive arthritis.\u00a0Scand J Rheumatol<\/em>\u00a034(4):251-259, 2005.<\/p>\n

Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, Deicher H. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup.\u00a0J Rheumatol<\/em>15(7):1109-1114, 1988.<\/p>\n

Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies.\u00a0Curr Rheumatol Rep<\/em>\u00a07(3):188-194, 2005.<\/p>\n

Ogasawara M, Kono DH, Yu DTY. Mimicry of human histocompatibility HLA-B27 antigens by\u00a0Klebsiella<\/em>pneumoniae<\/em>.\u00a0Infect Immun<\/em>\u00a051(3):901-908, 1986.<\/p>\n

 <\/p>\n

O\u2019Mahony S, Anderson N, Nuki G, Ferguson A. Systemic and mucosal antibodies to\u00a0Klebsiella<\/em>\u00a0in patients with ankylosing spondylitis and Crohn\u2019s disease.\u00a0Ann Rheum Dis<\/em>\u00a051(12):1296-1300, 1992.<\/p>\n

Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study).\u00a0J Rheumatol<\/em>\u00a029(3):511-515, 2002.<\/p>\n

Porzio V, Biasi G, Corrado A, De Santi M, Vindigni C, Viti S, Bayeli PF, Marcolongo R. Intestinal histological and ultrastructural inflammatory changes in spondyloarthropathy and rheumatoid arthritis.\u00a0Scand J Rheumatol<\/em>\u00a026(2):92-98, 1997.<\/p>\n

Rambukkana A, Das PK, Witkamp L, Yong S, Meinardi MM, Bos JD. Antibodies to mycobacterial 65-kDa\u00a0heat shock protein<\/a>\u00a0and other immunodominant antigens in patients with psoriasis.\u00a0J Invest Dermatol<\/em>\u00a0100(1):87-92, 1993.<\/p>\n

Rashid T, Ebringer A. Ankylosing spondylitis is linked to\u00a0Klebsiella<\/em>-the evidence.\u00a0Clin Rheumatol<\/em>26(6):858-864, 2007.<\/p>\n

 <\/p>\n

Rashid T, Ebringer A, Tiwana H, Fielder M. Role of\u00a0Klebsiella<\/em>\u00a0and collagens in Crohn\u2019s disease: A new prospect in the use of low-starch diet.\u00a0Eur J Gastroenterol Hepatol<\/em>\u00a021(8):843-849, 2009.<\/p>\n

 <\/p>\n

Renaud C, Ovetchkine P, Bortolozzi P, Saint-Cyr C, Tapiero B. Fatal\u00a0group A Streptococcus<\/a>\u00a0pupura fulminans in a child receiving TNF-\u03b1 blocker.\u00a0Eur J Pediatr<\/em>\u00a0170(5):657-660, 2011.<\/p>\n

 <\/p>\n

Rimbas M, Marinescu M, Voiosu MR, Baicus CR, Caraiola S, Nicolau A, Nitescu D, Badea GC, Parvu MI. NSAID-induced deleterious effects on the proximal and mid small bowel in seronegative spondyloarthropathy patients.\u00a0World J Gastroenterol<\/em>\u00a017(8):1030-1035, 2011.<\/p>\n

 <\/p>\n

Sany J, Rosenberg F, Panis G, Serre H. Unclassified HLA-B27 inflammatory rheumatic diseases: followup of 23 patients.\u00a0Arthritis Rheum<\/em>\u00a023(2):258-259, 1980.<\/p>\n

Schattenkirchner M, Kruger K. Natural course and prognosis of HLA-B27-positive oligoarthritis.\u00a0Clin Rheumatol<\/em>\u00a06(Suppl 2):83-86, 1987.<\/p>\n

Schlosstein L, Terasaki PI, Bluestone E, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis.\u00a0N Engl J Med<\/em>\u00a0288(14):704-706, 1973.<\/p>\n

 <\/p>\n

Schwimmbeck PL, Yu DTY, Oldstone MBA. Autoantibodies to HLA-B27 in the sera of HLA-B27 patients with ankylosing spondylitis and Reiter\u2019s syndrome: Molecular mimicry with\u00a0Klebsiella<\/em>pneumoniae<\/em>\u00a0as potential mechanism of\u00a0autoimmune disease<\/a>.\u00a0J Exp Med<\/em>\u00a0166(1):173-181, 1987.<\/p>\n

 <\/p>\n

Sieper J. Management of ankylosing spondylitis.\u00a0In<\/em>:\u00a0Rheumatology<\/em>. Hochberg MC, Silman AJ, et al. (eds.). pp. 1143-1164. Elsevier-Mosby, St. Louis, Missouri, USA, 2008.<\/p>\n

 <\/p>\n

Song IH, Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides.\u00a0Curr Opin Rheumatol<\/em>\u00a023(4):346-351, 2011.<\/p>\n

 <\/p>\n

Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, Bansal S, Ebringer A. Antibodies to\u00a0Klebsiella<\/em>,\u00a0Proteus<\/em>\u00a0and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis.\u00a0J Rheumatol<\/em>\u00a024(1):109-114, 1997a.<\/p>\n

 <\/p>\n

Tani Y, Sato H, Tanaka N, Mori K, Doida Y, Hukuda S. Serum IgA1 and IgA2 subclass antibodies against collagens in patients with ankylosing spondylitis.\u00a0Scand J Rheumatol<\/em>\u00a026(5):380-382, 1997b.<\/p>\n

 <\/p>\n

Thomas GP, Brown MA. Genomics of ankylosing spondylitis.\u00a0Discov Med<\/em>\u00a010(52):263-271, 2010.<\/p>\n

 <\/p>\n

Tiwana H, Wilson C, Walmsley RS, Wakefield AJ, Smith MS, Cox NL, Hudson MJ, Ebringer A. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn\u2019s disease and ulcerative colitis.\u00a0Rheumatol Int<\/em>\u00a017(1):11-16, 1997.<\/p>\n

 <\/p>\n

Tiwana H, Walmsley RS, Wilson C, Yiannakou JY, Ciclitira PJ, Wakefield AJ, Ebringer A. Characterization of the humoral immune response to\u00a0Klebsiella<\/em>\u00a0species in inflammatory bowel disease and ankylosing spondylitis.\u00a0Br J Rheumatol<\/em>\u00a037(5):525-531, 1998.<\/p>\n

Tiwana H, Natt RS, Benitez-Brito R, Shah S, Wilson C, Bridger S, Harbord M, Sarner M, Ebringer A. Correlation between the immune responses to collagens type I, III, IV and V and\u00a0Klebsiella pneumoniae\u00a0<\/em>in patients with Crohn\u2019s disease and ankylosing spondylitis.\u00a0Rheumatology (Oxford)<\/em>40(1):15-23, 2001.<\/p>\n

Towers RJ, Bolm M, Currie BJ, Chhatwal GS, Fagan PK. Autoantigens identified by screening a human heart\u00a0cDNA library<\/a>\u00a0with acute rheumatic fever sera.\u00a0Ann N Y Acad Sci<\/em>\u00a01173:83-91, 2009.<\/p>\n

 <\/p>\n

Townes JM. Reactive arthritis after enteric infections in the United States: the problem of definition.\u00a0Clin Infect Dis<\/em>\u00a050(2):247-254, 2010.<\/p>\n

 <\/p>\n

Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease.\u00a0Drug Des Devel Ther<\/em>\u00a05:185-210, 2011.<\/p>\n

 <\/p>\n

Uppal SS, Abraham M, Chowdhury RI, Kumari R, Pathan EM, Al-Rashed A. Ankylosing spondylitis and undifferentiated\u00a0spondyloarthritis<\/a>\u00a0in Kuwait: a comparison between Arabs and South Asians.\u00a0Clin Rheumatol<\/em>\u00a025(2):219-224, 2006.<\/p>\n

Welsh J, Avakian H, Cowling P, Ebringer A, Wooley P, Panayi G, Ebringer R. Ankylosing spondylitis, HLA-B27 and\u00a0Klebsiella<\/em>. I. Cross-reactivity studies with rabbit antisera.\u00a0Br J Exp Pathol<\/em>\u00a061(1):85-91, 1980.<\/p>\n

 <\/p>\n

Wilson C, Rashid T, Tiwana H, Beyan H, Hughes L, Bansal S, Ebringer A, Binder A. Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis.\u00a0J Rheumatol<\/em>30(5):972-978, 2003.<\/p>\n

 <\/p>\n

Wright V. Seronegative polyarthritis: a unified concept.\u00a0Arthritis Rheum<\/em>\u00a021(6):619-633, 1978.<\/p>\n

[Discovery Medicine<\/em>;\u00a0<\/strong>ISSN: 1539-6509;\u00a0<\/strong>Discov Med<\/em>\u00a012(64):187-194, September 2011.\u00a0<\/strong>Copyright \u00a9 Discovery Medicine. All rights reserved.]<\/strong><\/p>\n

 <\/p>\n

Fuente: \/ Source:\u00a0http:\/\/www.discoverymedicine.com\/Taha-Rashid\/2011\/09\/12\/gut-mediated-and-hla-b27-associated-arthritis-an-emphasis-on-ankylosing-spondylitis-and-crohns-disease-with-a-proposal-for-the-use-of-new-treatment\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Author:\u00a0Taha Rashid Specialty:\u00a0Immunology,\u00a0Internal Medicine Institution: Analytical Sciences Group, Kings College London Address: London, SE1 9NN, United Kingdom Author:\u00a0Alan Ebringer Specialty:\u00a0Immunology,\u00a0Internal Medicine Institution: Analytical Sciences Group, Kings College London Address: London, SE1 9NN, United Kingdom Abstract:\u00a0Ankylosing spondylitis (AS) and Crohn’s disease (CD), especially when associated with spondylitis are interrelated conditions included within the categories of spondyloarthropathic…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[6,9],"tags":[],"_links":{"self":[{"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/posts\/259"}],"collection":[{"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/comments?post=259"}],"version-history":[{"count":7,"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/posts\/259\/revisions"}],"predecessor-version":[{"id":269,"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/posts\/259\/revisions\/269"}],"wp:attachment":[{"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/media?parent=259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/categories?post=259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/davidzamorano.com\/espondilitis\/wp-json\/wp\/v2\/tags?post=259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}